BlinkBio, a Jupiter, Florida-based biotech company, received funding from the Florida Institute for the Commercialization of Public Research.
The amount of the deal was not disclosed.
The company intends to use the funds to continue to expand its development efforts.
Led by Colin Goddard, Ph.D., Chief Executive Officer, BlinkBio leverages technology developed at The Scripps Research Institute to assemble a proprietary suite of assets for the development of novel Drug Conjugate therapies for the treatment of cancer and other diseases called Tunable Drug Conjugates (TDCs). Capable of enhanced tumor penetration, rapid payload release and systemic clearance following dosing, TDCs are designed to drive higher payload concentrations within tumor cells while minimizing toxicities to patients.